Last reviewed 2026-04-20 · How we verify

Srilane (IDROCILAMIDE)

Phase 2 active Small molecule

Srilane (generic name: IDROCILAMIDE) is a idrocilamide drug. It is currently in Phase 2 development.

Idrocilamide is thought to work by inhibiting the enzyme carbonic anhydrase, which plays a role in maintaining acid-base balance in the body.

Idrocilamide is a small molecule drug in the idrocilamide class, but its target and approved indications are unknown. Its commercial status is unclear, and it is not known if it is patented or available as a generic. The half-life of idrocilamide is approximately 1.35 hours, but its bioavailability and off-patent status are unknown. As a result, there is limited information available about this compound. Further research is needed to determine its clinical utility and safety profile.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	IDROCILAMIDE
Drug class	idrocilamide
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of it like a leaky faucet - carbonic anhydrase helps regulate the amount of acid in the body. When it's working properly, it helps keep the body's pH levels in balance. Idrocilamide may help by blocking this enzyme, which can help reduce the amount of acid in the body.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Srilane CI brief — competitive landscape report
Srilane updates RSS · CI watch RSS

Frequently asked questions about Srilane

What is Srilane?

Srilane (IDROCILAMIDE) is a idrocilamide drug.

How does Srilane work?

Idrocilamide is thought to work by inhibiting the enzyme carbonic anhydrase, which plays a role in maintaining acid-base balance in the body.

What is the generic name of Srilane?

IDROCILAMIDE is the generic (nonproprietary) name of Srilane.

What drug class is Srilane in?

Srilane belongs to the idrocilamide class. See all idrocilamide drugs at /class/idrocilamide.

What development phase is Srilane in?

Srilane is in Phase 2.

Drug class: All idrocilamide drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing